The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy

Thomas G. Martin, MD, provides expert guidance on bridging and other treatment strategies for the real-world implementation of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, including up-to-date clinical trial data and future directions affecting the placement of CAR T-cell therapy in the treatment landscape.

Share

Program Content

Activities

CAR T Bridging for MM: Module
The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2023

Expires: July 16, 2024

Activities

CAR T Bridging for MM: Slideset
The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2023

Faculty

cover img faculity

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Lead, Cancer Immunology and Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb